Year 2022 / Volume 29 / Supplement 1

Abstract PDF HTML

Cannabinoids Article

Current evidence of medical cannabis treatment in patients with chronic pain

Rev. Soc. Esp. Dolor. 2022; 29(13): 10-13 / DOI: 10.20986/resed.2022.4024/2022

Juan Fernando García, Jesús de Santiago


ABSTRACT

Medical cannabis has been promoted by the media and by public opinion. The cannabis herb and cannabis-based medicines have bypassed traditional evidence-based studies, and have been legalized in many countries without going through the usual path of drug approval. The medical community must be aware of the current evidence in this regard in order to appropriately advise patients. This review will explain the current status of the evidence, the obstacles encountered to obtain evidence, and the positions of the respective pain societies regarding the use of medicinal cannabis for the treatment of pain.



RESUMEN

El cannabis medicinal ha sido promovido por los medios de comunicación y por la opinión pública en general. La planta del cannabis y los medicamentos a base de cannabis (CbM) han pasado por alto los estudios tradicionales basados en la evidencia, y han sido legalizados en muchos países sin pasar por el camino habitual de aprobación de los medicamentos. La comunidad médica debe conocer la evidencia actual al respecto para poder asesorar de manera competente a los pacientes. Esta revisión explicará brevemente la situación actual de la evidencia, de los obstáculos encontrados y de los posicionamientos de las respectivas sociedades del dolor respecto a la utilización del cannabis medicinal para el tratamiento del dolor.





Complete Article

Nuevo comentario

Security code:
CAPTCHA code image
Speak the codeChange the code
 

Comentarios

No comments in this article

Bibliografía

1. Torralba A, Miquel A, Darba J. Situación actual del dolor crónico en España: iniciativa "Pain Proposal". Rev Soc Esp Dolor. 2014;21(1):16-22. DOI: 10.4321/S1134-80462014000100003.
DOI: 10.4321/S1134-80462014000100003
2. Rodriguez MJ, García AJ. Costes del dolor neuropático según etiología en las Unidades del Dolor en España. Rev Soc Esp Dolor. 2007;6:404-15.
3. Finnerup NB, Attal N, Haroutounian S, McNicol E, Baron R, Dworkin RH, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol. 2015;14(2):162-73.
DOI: 10.1016/S1474-4422(14)70251-0
4. Fitzcharles MA, Eisenberg E. Medical cannabis: a forward vision for the clinician. Eur J Pain. 2018;22(3):485-91.
DOI: 10.1002/ejp.1185
5. Fitzcharles MA, Shir Y, Häuser W. Medical cannabis: strengthening evidence in the face of hype and public pressure. CMAJ. 2019;191(33):E907-8.
DOI: 10.1503/cmaj.190509
6. Teede R-D, Rief W, Barke A, Aziz Q, Bennett MI, Benoliel R, et al. Chronic pain as a symptom or a disease: the IASP clas- sification of chronic pain for the international classification of diseases [ICD-11]. Pain. 2019;160(1):19-27.
DOI: 10.1097/j.pain.0000000000001384
7. Lynch mE, Campbell F. Cannabinoids for treatment of chronic non cancer pain. a systematic review of randomized trials. Br J Clin Pharmacol. 2011 ;72(5):735-44.
8. Chang Y, Zhu M, Vannabouathong C, Mundi R, Chou RS, Bhandari M. Medical Cannabis for Chronic Noncancer Pain: A Systematic Review of Health Care Recommendations. Pain Res Manag. 2021;2021:8857948.
DOI: 10.1155/2021/8857948
9. Fisher E, Moore RA, Fogarty AE, Finn DP, Finnerup NB, Gilron I, et al. Cannabinoids, cannabis, and cannabis-based medicine for pain management: a systematic review of randomised controlled trials. Pain. 2021;162(Suppl 1):S45-S66.
DOI: 10.1097/j.pain.0000000000001929
10. Mücke M, Phillips T, Radbruch L, Petzke F, Häuser W. Cannabis-based medicines for chronic neuropathic pain in adults. Cochrane Database Syst Rev. 2018;3(3):CD012182.
DOI: 10.1002/14651858.CD012182.pub2
11. Mu A, Weinberg E, Moulin DE, Clarke H. Pharmacologic management of chronic neuropathic pain: Review of the Canadian Pain Society consensus statement. Can Fam Physician. 2017;63(11):844-52.
12. Whiting PF, Wolff RF, Deshpande S, Di Nisio M, Duffy S, Hernandez AV, et al. Cannabinoids for Medical Use: A Systematic Review and Meta-analysis. JAMA. 2015;313(24):2456-73.
DOI: 10.1001/jama.2015.6358
13. Sainsbury B, Bloxham J, Pour MH, Padilla M, Enciso R. Efficacy of cannabis-based medications compared to placebo for the treatment of chronic neuropathic pain: a systematic review with meta-analysis. J Dent Anesth Pain Med. 2021;21(6):479-506.
DOI: 10.17245/jdapm.2021.21.6.479
14. Noori A, Miroshnychenko A, Shergill Y, Ashoorion V, Rehman Y, Couban RJ, et al. Opioid-sparing effects of medical cannabis or cannabinoids for chronic pain: a systematic review and meta-analysis of randomised and observational studies. BMJ Open. 2021;11(7):e047717.
DOI: 10.1136/bmjopen-2020-047717
15. Moulin D, Boulanger A, Clark AJ, Clarke H, Dao T, Finley GA, et al. Pharmacological management of chronic neuropathic pain: revised consensus statement from the Canadian Pain Society. Pain Res Manag. 2014;19(6):328-35.
DOI: 10.1155/2014/754693
16. Häuser W, Finn DP, Kalso E, Krcevski-Skvarc N, Kress HG, Morlion B, et al. European Pain Federation (EFIC) position paper on appropriate use of cannabis-based medicines and medical cannabis for chronic pain management. Eur J Pain. 2018;22(9):1547-64.
DOI: 10.1002/ejp.1297
17. Petzke F, Karst M, Gastmeier K, Radbruch L, Steffen E, Häuser W. Ad-hoc-Kommission der Deutschen Schmerzgesellschaft “Cannabis in der Medizin.” Position paper on medical cannabis and cannabis-based medicines in pain medicine [in German]. Schmerz. 2019;33(5):449-65.
DOI: 10.1007/s00482-019-00407-2
18. National Institute for Health and Care Excellence Neuropathic pain in adults: pharmacological management in non-specialist settings. London: National Institute for Health and Care Excellence (UK). 2020.
19. Moisset X, Bouhassira D, Avez Couturier J, Alchaar H, Conradi S, Delmotte MH, et al. Pharmacological and non-pharmacological treatments for neuropathic pain: systematic review and French recommendations. Rev Neurol (Paris). 2020;176(5):325-52.
DOI: 10.1016/j.neurol.2020.01.361
20. Haroutounian S, Arendt-Nielsen L, Belton J, Blyth FM, Degenhardt L, Di Forti M, et al. International Association for the Study of Pain Presidential Task Force on Cannabis and Cannabinoid Analgesia: research agenda on the use of cannabinoids, cannabis, and cannabis-based medicines for pain management. Pain. 2021;162(Suppl. 1):S117-24.
DOI: 10.1097/j.pain.0000000000002266
21. Eisenberg E, Morlion B, Brill S, Häuser W. Medicinal cannabis for chronic pain: The bermuda triangle of low-quality studies, countless meta-analyses and conflicting recommendations. Eur J Pain. 2022;26(6):1183-5.
DOI: 10.1002/ejp.1946
22. Wang L, Hong PJ, May C, Rehman Y, Oparin Y, Hong CJ, et al. Medical cannabis or cannabinoids for chronic non-cancer and cancer related pain: a systematic review and meta-analysis of randomised clinical trials. BMJ. 2021;374:n1034.
DOI: 10.1136/bmj.n1034
23. Chung M, Kim HK, Abdi S. Update on cannabis and cannabinoids for cancer pain. Curr Opin Anaesthesiol. 2020;33(6):825-31.
DOI: 10.1097/ACO.0000000000000934
24. Baswan SM, Klosner AE, Glynn K, Rajgopal A, Malik K, Yim S, et al. Therapeutic Potential of Cannabidiol (CBD) for Skin Health and Disorders. Clin Cosmet Investig Dermatol. 2020;13:927-42.
DOI: 10.2147/CCID.S286411

Artículos relacionados

Care needs of intrathecal infusion therapy in patients with cancer pain

Rev. Soc. Esp. Dolor. 2023; 30(4): 227-242 / DOI: 10.20986/resed.2024.4099/2023

Continuous electrical stimulation for the treatment of trigeminal neuralgia. A systematic review

Rev. Soc. Esp. Dolor. 2023; 30(4): 217-226 / DOI: 10.20986/resed.2023.4043/2022

Ultrasound-guided ankle nerve block as adjuvant therapy in chronic pain after occupational injury.

Rev. Soc. Esp. Dolor. 2023; 30(3): 178-186 / DOI: 10.20986/resed.2023.4035/2022

Impact on quality of life, depression and analgesic use, are associated with suffering in fibromyalgia patients. A cross-sectional study

Rev. Soc. Esp. Dolor. 2023; 30(3): 159-167 / DOI: 10.20986/resed.2023.4061/2023

Effect of therapeutic exercise in persons with sacroiliac joint dysfunction: a systematic review and meta-analysis

Rev. Soc. Esp. Dolor. 2023; 30(2): 95-108 / DOI: 10.20986/resed.2023.4034/2022

Observational, prospective and multicenter study on the use of transmucosal fentanyl citrate in regular clinical practice for the control of breakthrough pain crises in cancer patients

Rev. Soc. Esp. Dolor. 2023; 30(2): 72-78 / DOI: 10.20986/resed.2023.4028/2022

Effectiveness of electroacupuncture and moxibustion in the treatment of postoperative anterior cruciate ligament graft pain with meniscal remodeling. Case study UNEVT 2022

Rev. Soc. Esp. Dolor. 2022; 29(3): 192-195 / DOI: 10.20986/resed.2022.4009/2022

Long-term effectiveness of epidural steroid injections after new episodes of low back pain in older adults

Rev. Soc. Esp. Dolor. 2022; 29(3): 175-186 / DOI: 10.1002/ejp.1975

Efficacy of physiotherapy on the anxiety and depression in patients with chronic pain: a systematic review

Rev. Soc. Esp. Dolor. 2022; 29(3): 157-168 / DOI: 10.20986/resed.2022.3994/2022

The biopsychosocial nature of chronic pelvic floor pain: a narrative review

Rev. Soc. Esp. Dolor. 2022; 29(2): 97-113 / DOI: 10.20986/resed.2022.3981/2022

Attitudes and current knowledge of the spanish pain treatment specialist regarding medical cannabis

Rev. Soc. Esp. Dolor. 2022; 29(13): 52-57 / DOI: 10.20986/resed.2022.4032/2022

Practical aspects of product selection and titration with medical cannabis for chronic pain management

Rev. Soc. Esp. Dolor. 2022; 29(13): 43-51 / DOI: 10.20986/resed.2022.4031/2022

Medical cannabis treatment in patients with visceral chronic pain

Rev. Soc. Esp. Dolor. 2022; 29(13): 32-42 / DOI: 10.20986/resed.2022.4030/2022

Is medical cannabis useful for the treatment of fibromyalgia?

Rev. Soc. Esp. Dolor. 2022; 29(13): 27-31 / DOI: 10.20986/resed.2022.4029/2022

Cannabinoids in neuropathic pain: lights and shadows

Rev. Soc. Esp. Dolor. 2022; 29(13): 20-26 / DOI: 10.20986/resed.2022.4027/2022

Medical cannabis and cancer: benefits for cancer pain and other related symptoms

Rev. Soc. Esp. Dolor. 2022; 29(13): 14-19 / DOI: 10.20986/resed.2022.4026/2022

Some preclinical results of cannabinoids and pain

Rev. Soc. Esp. Dolor. 2022; 29(13): 3-9 / DOI: 10.20986/resed.2022.4033/2022

Lights and shadows of treating pain with medical cannabis

Rev. Soc. Esp. Dolor. 2022; 29(13): 1-2 / DOI: 10.20986/resed.2022.4036/2022

Complex regional pain syndrome, rehabilitation, pharmacotherapy, psychology.

Rev. Soc. Esp. Dolor. 2022; 29(1): 34-50 / DOI: 10.20986/resed.2022.3978/2022

Use of botulinum toxin for pain after amputation

Rev. Soc. Esp. Dolor. 2021; 28(6): 332-342 / DOI: 10.20986/resed.2022.3943/2021

Preliminary study on the evaluation of mechanical pressure pain and central pain modulation mechanisms by algometry in an anesthesia unit

Rev. Soc. Esp. Dolor. 2021; 28(6): 311-318 / DOI: 10.20986/resed.2022.3885/2021

A new paradigm for the treatment of knee osteoarthritis: the role of hyaluronic acid, platelet-rich plasma (PRP) and ozone in the modulation of inflammation: a review

Rev. Soc. Esp. Dolor. 2021; 28(5): 282-291 / DOI: 10.20986/resed.2021.3903/2021

Efficacy and complications of analgesic techniques for the treatment of moderate to severe postoperative acute pain

Rev. Soc. Esp. Dolor. 2021; 28(5): 264-265 / DOI: 10.20986/resed.2021.3942/2021

Descriptive study on the profile of patients sent to the Chronic Pain Treatment Unit of the University Hospital of Gran Canaria Dr. Negrín (UTDC-HUGCDN) as a basis for the reorganization of this

Rev. Soc. Esp. Dolor. 2021; 28(5): 254-263 / DOI: 10.20986/resed.2021.3939/2021

The unsolved problem of postoperative pain: critical analysis and prospects for improvement

Rev. Soc. Esp. Dolor. 2021; 28(4): 232-238 / DOI: 10.20986/resed.2021.3917/2021

Dorsal root ganlion pulsed radiofrequency for lumbosacral radicular pain: a narrative review

Rev. Soc. Esp. Dolor. 2021; 28(4): 219-231 / DOI: 10.20986/resed.2021.3882/2021

Clinical recommendations for rehabilitation of people with fibromyalgia. A narrative review

Rev. Soc. Esp. Dolor. 2021; 28(4): 194-210 / DOI: 10.20986/resed.2021.3932/2021

Genicular nerve radiofrequency in osteoarthritis-related chronic knee pain

Rev. Soc. Esp. Dolor. 2021; 28(3): 154-168 / DOI: 10.20986/resed.2021.3900/2021

Prescribing habits for neuropathic pain management in Spain: results of the survey of the neuropathic pain working group of the Spanish Pain Society

Rev. Soc. Esp. Dolor. 2021; 28(3): 137-147 / DOI: 10.20986/resed.2021.3911/2021

Botulinum toxin for the treatment of myofascial pain syndrome

Rev. Soc. Esp. Dolor. 2021; 28(2): 100-110 / DOI: 10.20986/resed.2021.3902/2021

Transfusions at the end of life. Review of some important considerations

Rev. Soc. Esp. Dolor. 2021; 28(1): 47-52 / DOI: 10.20986/resed.2021.3831/2020

Inflammatory mediators: its connection with chronic pain and associated problems. Review

Rev. Soc. Esp. Dolor. 2021; 28(1): 37-46 / DOI: 10.20986/resed.2021.3841/2020

Interventional management of osteoarthritic pain

Rev. Soc. Esp. Dolor. 2021; 28(13): 85-90 / DOI: 10.20986/resed.2021.3853/2020

New pharmacological targets for osteoarthritis induced pain

Rev. Soc. Esp. Dolor. 2021; 28(13): 57-63 / DOI: 10.20986/resed.2021.3863/2020

Opioids in osteoarthritis

Rev. Soc. Esp. Dolor. 2021; 28(13): 49-56 / DOI: 10.20986/resed.2021.3855/2020

News in the clinical practice guidelines regarding the treatment of the hip, knee and hands osteoarthritis

Rev. Soc. Esp. Dolor. 2021; 28(13): 38-42 / DOI: 10.20986/resed.2021.3870/2020

Adaptation of the chronic pain unit of the Hospital Complex from Vigo to the state of alarm due to the SARS-CoV-2 pandemic

Rev. Soc. Esp. Dolor. 2020; 27(6): 392-393 / DOI: 10.20986/resed.2020.3827/2020

Effectiveness and current recommendation of manual therapy on hip osteoarthritis. An overview

Rev. Soc. Esp. Dolor. 2020; 27(6): 375-391 / DOI: 10.20986/resed.2021.3835/2020

Calcific tendinitis of the shoulder: risk factors and effectiveness of iontophoresis with acetic acid 5 % plus ultrasound: prospective quasi-experimental study at 5 years with 138 cases

Rev. Soc. Esp. Dolor. 2020; 27(6): 340-348 / DOI: 10.20986/resed.2020.3842/2020

Opioid misuse in patients with cancer pain: an integrative systematic review of the literature

Rev. Soc. Esp. Dolor. 2020; 27(5): 306-315 / DOI: 10.20986/resed.2020.3801/2020

Therapeutic failure of the lumbar medial branch block and its relation to obesity. Retrospective cohort study

Rev. Soc. Esp. Dolor. 2020; 27(5): 298-305 / DOI: 10.20986/resed.2020.3829/2020

Splanchnic nerve block for the treatment of benign chronic abdominal pain. a case report and literature review

Rev. Soc. Esp. Dolor. 2020; 27(4): 273-277 / DOI: 10.20986/resed.2020.3818/2020

Gender determinants in the approach to chronic pain

Rev. Soc. Esp. Dolor. 2020; 27(4): 252-256 / DOI: 10.20986/resed.2020.3802/2020

Spanish Pain Society (SPS). Healthcare recommendations for pain units in the face of progressive normalization of activity during the COVID-19 pandemic

Rev. Soc. Esp. Dolor. 2020; 27(3): 192-215 / DOI: 10.20986/resed.2020.3821/2020

Management of breakthrough pain associated with the cure of skin ulcers

Rev. Soc. Esp. Dolor. 2020; 27(2): 113-126 / DOI: 10.20986/resed.2020.3755/2019

Intra-articular ozone modulates inflammation, ameliorates pain and stiffness, improves function and has anabolic effect on knee osteoarthritis: a prospective quasiexperimental before-and-after study, 115 patients

Rev. Soc. Esp. Dolor. 2020; 27(2): 78-88 / DOI: 10.20986/resed.2020.3775/2019

Effectiveness of patient-controlled analgesia in acute and chronic pain after cardiac surgery: a prospective study

Rev. Soc. Esp. Dolor. 2020; 27(1): 24-36 / DOI: 10.20986/resed.2020.3747/2019

Efficacy of pregabalin, gabapentin and duloxetine in neuropathic pain verified by the p-curve analysis

Rev. Soc. Esp. Dolor. 2020; 27(1): 16-23 / DOI: 10.20986/resed.2020.3727/2019

Spinal stimulation modulated automatically. Evidence of closed stimulation systems: towards the pain pacemaker

Rev. Soc. Esp. Dolor. 2020; 27(1): 5-6 / DOI: 10.20986/resed.2020.3793/2020

Considerations for the use of evidence-based practice in the management of people with pain

Rev. Soc. Esp. Dolor. 2019; 26(6): 374-375 / DOI: 10.20986/resed.2019.3712/2018

Key factors governing spinal cord opioid bioavailability in the management of acute pain

Rev. Soc. Esp. Dolor. 2019; 26(6): 359-367 / DOI: 10.20986/resed.2019.3737/2019

Neurolytic procedures for pancreatic cáncer pain: a systematic review and a proposal for an algorithm treatment

Rev. Soc. Esp. Dolor. 2019; 26(6): 342-358 / DOI: 10.20986/resed.2019.3715/2018

Connexins in chronic pain. A new target?

Rev. Soc. Esp. Dolor. 2019; 26(6): 322-323 / DOI: 10.20986/resed.2019.3785/2019

The use of new technologies in patients with chronic pain. A reality that cannot be denied

Rev. Soc. Esp. Dolor. 2019; 26(5): 259-260 / DOI: 10.20986/resed.2019.3766/2019

Role of depressive symptomatology, catastrophism and expectation in the efficacy of interventional treatment in chronic low back pain

Rev. Soc. Esp. Dolor. 2019; 26(4): 227-232 / DOI: 10.20986/resed.2019.3704/2018

The new international classification of diseases (ICD-11) and chronic pain. Pragmatical implications

Rev. Soc. Esp. Dolor. 2019; 26(4): 209-210 / DOI: 10.20986/resed.2019.3752/2019

Evidence and foresight of ultrasound-guided blocks for the painful shoulder

Rev. Soc. Esp. Dolor. 2019; 26(3): 144-145 / DOI: 10.20986/resed.2019.3741/2019

Explanations on the article “Recommendations based on evidence for the management of neuropathic pain (review of the literature)”

Rev. Soc. Esp. Dolor. 2019; 26(2): 134-137 / DOI: 10.20986/resed.2019.3723/2019

Profiles of personality and resilience in chronic pain: utility of the CDRISC-10 to discriminate between resilient and vulnerable types

Rev. Soc. Esp. Dolor. 2019; 26(2): 72-80 / DOI: 10.20986/resed.2018.3670/2018

Fibromyalgia and cortical reorganization. What does the evidence say?

Rev. Soc. Esp. Dolor. 2019; 26(1): 61-62 / DOI: 10.20986/resed.2017.3595/2017

Oxytocin and chronic pain in humans

Rev. Soc. Esp. Dolor. 2019; 26(1): 52-58 / DOI: 10.20986/resed.2018.3664/2018

Influence of psychosocial factors in the experience of musculoskeletal pain: a literatura review

Rev. Soc. Esp. Dolor. 2019; 26(1): 44-51 / DOI: 10.20986/resed.2018.3679/2018

Project adapta: adequacy of treatment in breakthrough cancer pain

Rev. Soc. Esp. Dolor. 2019; 26(1): 31-43 / DOI: 10.20986/resed.2018.3661/2018

Non-steroidal anti-inflammatory drugs and cardiovascular safety: is naproxen safer than celecoxib? New evidences

Rev. Soc. Esp. Dolor. 2018; 25(6): 365-367 / DOI: 10.20986/resed.2017.3549/2016

Evidence-based recommendations for the management of neuropathic pain (review of the literature)

Rev. Soc. Esp. Dolor. 2018; 25(6): 349-358 / DOI: 10.20986/resed.2018.3673/2018

Opinaudit study: clinical uses in breakthrough pain, is scientific evidence being followed up?

Rev. Soc. Esp. Dolor. 2018; 25(6): 325-334 / DOI: 10.20986/resed.2018.3634/2017

Implications of bioethics in the treatment of chronic pain: the change of paradigms

Rev. Soc. Esp. Dolor. 2018; 25(5): 291-300 / DOI: 10.20986/resed.2018.3666/2018

Farmacologic adyuvants with saving effect of opioids in the perioperative period

Rev. Soc. Esp. Dolor. 2018; 25(5): 278-290 / DOI: 10.20986/resed.2018.3663/2018

Pain in the elderly and in patients with cognitive deficit. A DELPHI study

Rev. Soc. Esp. Dolor. 2018; 25(5): 251-262 / DOI: 10.20986/resed.2017.3621/2017

Potential uses of Mirtazapine in palliative care beyond its antidepressant effect

Rev Soc Esp Dolor 2018; 25(1): 37-44 / DOI: 10.20986/resed.2017.3575/2017

Characterization of chest pain in patients attending the emergency department of a high-complexity-level healthcare institution, during 2014-2015, in Medellín, Colombia

Rev Soc Esp Dolor 2017; 24(6): 288-293 / DOI: 10.20986/resed.2017.3571/2017

Chronic pain: relationship with prefrontal symptoms and perceived stress

Rev Soc Esp Dolor 2017; 24(4): 179-187 / DOI: 10.20986/resed.2017.3540/2016

Control of symptoms in terminally ill patients: effectiveness of opioid treatment for breakthrough dyspnea

Rev Soc Esp Dolor 2017; 24(4): 161-168 / DOI: 10.20986/resed.2017.3582/2017

Prevalence of breakthrough pain associated with chronic low back pain in Andalusia (COLUMBUS study)

Rev Soc Esp Dolor 2017; 24(3):116-124 / DOI: 10.20986/resed.2017.3548/2016

Prescribing strong opioids in patients with non-cancer pain: a description of their characteristics in an area of primary healthcare assistance

Rev Soc Esp Dolor 2017; 24(1): 19-26 / DOI: 10.20986/resed.2016.3471/2016

Instrucciones para citar

García J, de Santiago J. Current evidence of medical cannabis treatment in patients with chronic pain. Rev Soc Esp Dolor 2022; 29(13): 10-13 / DOI: 1020986/resed20224024/2022


Descargar a un gestores de citas

Descargue la cita de este artículo haciendo clic en uno de los siguientes gestores de citas:

Métrica

Este artículo ha sido visitado 8805 veces.
Este artículo ha sido descargado 3 veces.

Estadísticas de Dimensions


Estadísticas de Plum Analytics

Ficha Técnica

Aceptado: 13/09/2022

Publicado: 28/10/2022


Compartir

Este artículo aun no tiene valoraciones.
Reader rating:
Rate this article:
Send by e-mail
© 2024 Revista de la Sociedad Española del Dolor
ISSN: 1134-8046   e-ISSN: 2254-6189

       Indexada en:
Política de Privacidad